Evidence map›Paper›PMID 29930161›Full record

Trial reportJournal of the American Society of Nephrology : JASN2018

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

Sophie M van den Belt, Hiddo J L Heerspink, Valentina Gracchi, Dick de Zeeuw, Elke Wühl, Franz Schaefer, ESCAPE Trial Group

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: AJournal of the American Society of Nephrology : JASN · 2020 · on this map
    Trial
  7. New therapeutic hope for rare podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  8. Proteinuria in adolescence.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sophie M van den BeltDepartments of Clinical Pharmacy and Pharmacology and s.m.van.den.belt@umcg.nl.
Hiddo J L HeerspinkDepartments of Clinical Pharmacy and Pharmacology and.
Valentina GracchiPediatric Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and.
Dick de ZeeuwDepartments of Clinical Pharmacy and Pharmacology and.
Elke WühlDepartment of Pediatric Nephrology, University Clinic Heidelberg, Heidelberg, Germany.
Franz SchaeferDepartment of Pediatric Nephrology, University Clinic Heidelberg, Heidelberg, Germany.
ESCAPE Trial Group
Heidelberg University · DEUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAngiotensin-Converting Enzyme InhibitorsArea Under CurveBlood PressureChildChild, PreschoolConfidence IntervalsDisease ProgressionFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidney Failure, ChronicLinear ModelsMaleMultivariate AnalysisAngiotensin-Converting Enzyme InhibitorsRamiprilACE inhibitionchildrenchronic kidney diseaseproteinuria

Identifiers

PMID29930161
PMCPMC6065076
OpenAlexW2809085611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.